Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.63 |
| ▸ | CTSS | P25774 | 3/20 | 0.63 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22371978 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345617 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371977 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL15671593 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL3087516 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL7345607 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL22371979 | 1.00 | CTSK (0.63) | CTSKCTSSPSENENCA2CA1 | |
| SCHEMBL59323 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL467994 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 | |
| SCHEMBL256794 | 0.93 | CTSK (0.61) | CTSKCTSSCA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050563-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2018-05-09 | — | — | EP | claimed |
| EP-2616067-B1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL]METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2016-05-18 | — | — | EP | claimed |
| US-20120136036-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2012-05-31 | — | — | US | claimed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | claimed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | claimed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | claimed |
| EP-4219460-B1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | SITARI PHARMA, INC., | 2025-01-09 | — | — | US | disclosed |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4219460-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | Sitari Pharma, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | SITARI PHARMA, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11254695-B2 | Soluble C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2022-01-27 | — | — | US | disclosed |
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | disclosed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-1990005141-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUKOCYTIC ELASTASE AND COLLAGENASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1990-05-17 | — | — | WO | disclosed |
| EP-0204775-A4 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE. | UNIV TROBE (AU) | 1989-10-04 | — | — | EP | disclosed |
| EP-0204775-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | AUSTRALIAN COMMERCIAL RESEARCH & DEVELOPMENT LIMITED (AU) | 1986-12-17 | — | — | EP | disclosed |
| WO-1986003746-A1 | AMINO ACID AND PEPTIDE INHIBITORS OF HUMAN LEUCOCYTIC ELASTASE | LA TROBE UNIVERSITY (AU) | 1986-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | CTSK 274/4885CTSS 157/4885PSENEN 3142/4885 |
| US-11548892-B1 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CTSK 469/4885CTSS 397/4885PSENEN 745/4885 |
| US-12152026-B2 | Transglutaminase 2 (TG2) inhibitors | TGM2, TGM3, TGM1 | CTSK 469/4885CTSS 397/4885PSENEN 745/4885 |
| US-20120136036-A1 | ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, EBP, CUTA | CTSK 1072/4885CTSS 1989/4885PSENEN 1467/4885 |
| US-20250011324-A1 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | TGM2, TGM3, TGM1 | CTSK 469/4885CTSS 397/4885PSENEN 745/4885 |
| US-11254695-B2 | Soluble C5aR antagonists | C5AR1, C3AR1, C5AR2 | CTSK 981/4885CTSS 753/4885PSENEN 1547/4885 |
| US-20220024949-A1 | CU-AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS | PCSK9, PCSK7, PCSK6 | CTSK 32/4885CTSS 309/4885PSENEN 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.